Preparing to Treat Concussions in Hockey Players Using a "From Ice to Axon and Astrocyte Repeated Measures Design"


About this study

The purpose of this study is to demonstrate the value of our objective diagnosis of concussion (ODC) components and to quantify severity. ODC components include: the NeuroCatch™ Platform [quantified electroencephalogram (qEEG)] developed by NeuroCatch Inc., the King-Devick Test (in association with Mayo Clinic) of rapid number naming, and blood biomarkers such as neurofilament light (NfL), neuron-specific enolase (NSE), and S100B.  Wearable accelerometers (Triax Technologies’ SIM-G, X2 Biosystems X Patch, and Prevent Biometrics’ Impact Monitor Mouthguard) and three camera video footage will also provide acceleration data to correlate to concussive injuries and mechanism of injury. Time on Ice tracking will allow for calculation of Individual Exposure Time (IET).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Consenting Junior A ice hockey players
  • Medically cleared to participate in hockey at the time of enrollment are eligible to participate in this study.

Exclusion Criteria:

  • Any players not medically cleared or for other reasons are restricted from hockey cannot participate in this study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Michael Stuart, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer